WO2003022871A3 - Nouveaux inhibiteurs de dipeptidylpeptidase i - Google Patents

Nouveaux inhibiteurs de dipeptidylpeptidase i Download PDF

Info

Publication number
WO2003022871A3
WO2003022871A3 PCT/EP2002/010020 EP0210020W WO03022871A3 WO 2003022871 A3 WO2003022871 A3 WO 2003022871A3 EP 0210020 W EP0210020 W EP 0210020W WO 03022871 A3 WO03022871 A3 WO 03022871A3
Authority
WO
WIPO (PCT)
Prior art keywords
unbranched
branched
chain
heteroaryl
amino acid
Prior art date
Application number
PCT/EP2002/010020
Other languages
English (en)
Other versions
WO2003022871A2 (fr
Inventor
Hans-Ulrich Demuth
Ulrich Heiser
Andre Niestroj
Original Assignee
Probiodrug Ag
Hans-Ulrich Demuth
Ulrich Heiser
Andre Niestroj
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Probiodrug Ag, Hans-Ulrich Demuth, Ulrich Heiser, Andre Niestroj filed Critical Probiodrug Ag
Priority to EP02779316A priority Critical patent/EP1423410A2/fr
Priority to AU2002342657A priority patent/AU2002342657A1/en
Priority to JP2003526944A priority patent/JP2005511505A/ja
Publication of WO2003022871A2 publication Critical patent/WO2003022871A2/fr
Publication of WO2003022871A3 publication Critical patent/WO2003022871A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne de nouveaux composés qui agissent en tant qu'inhibiteurs spécifiques de la cystéine protéase dipeptidylpeptidase I (DP I), lesquels sont représentés par la formule générale (I), ainsi que des sels pharmaceutiquement acceptables de ceux-ci. Dans cette formule générale (I), R représente un résidu d'acyle comprenant un uréthanne et un peptide, ou une chaîne alkyle C1-C9 ramifiée ou non ramifiée, une chaîne alcényle C2-C9 ramifiée ou non ramifiée, une chaîne alcynyle C2-C9 ramifiée ou non ramifiée, un cycloalkyle C3-C9, un carbocycle C4-C9, un aryle C5-C14, un hétéroaryle C3-C9, un hétérocycle C3-C9, tous les résidus susmentionnnés pouvant être éventuellement substitués, ou représente H, AS représentant un acide aminé ou un peptide mimétique de celui-ci. Cet acide aminé possède une liaison peptidique avec R, et R' représente une chaîne alkyle C1-C9 ramifiée ou non ramifiée, une chaîne alcényle C2-C9 ramifiée ou non ramifiée, une chaîne alcynyle C2-C9 ramifiée ou non ramifiée, un cycloalkyle C3-C9, un cycloalcényle C4-C9, un hétérocycloalkyle C2-C9, un hétérocycloalcényle C3-C9, un aryle C5-C14, un hétéroaryle C3-C9, un hétérocycle C3-C9, le résidu hétérocylcoalkyle, hétérocycloalcényle, hétéroaryle, hétérocylcique pouvant posséder jusqu'à 6 hétéroatomes sur le cycle, un acide aminé ou un peptide mimétique de celui-ci, touts les résidus susmentionnés pouvant être éventuellement substitués, ou représente H.
PCT/EP2002/010020 2001-09-06 2002-09-06 Nouveaux inhibiteurs de dipeptidylpeptidase i WO2003022871A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP02779316A EP1423410A2 (fr) 2001-09-06 2002-09-06 Inhibiteurs de dipeptidylpeptidase i renfermant un group hydroxylamino c-terminal
AU2002342657A AU2002342657A1 (en) 2001-09-06 2002-09-06 Peptides having a c- terminal hydroxylamino group as inhibitors of dipeptidyl peptidase i
JP2003526944A JP2005511505A (ja) 2001-09-06 2002-09-06 ジペプチジルペプチダーゼｉの新規な阻害剤

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10143840A DE10143840A1 (de) 2001-09-06 2001-09-06 Neue Inhibitoren der Dipeptidylpeptidase I
DE10143840.0 2001-09-06

Publications (2)

Publication Number Publication Date
WO2003022871A2 WO2003022871A2 (fr) 2003-03-20
WO2003022871A3 true WO2003022871A3 (fr) 2003-11-13

Family

ID=7698010

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/010020 WO2003022871A2 (fr) 2001-09-06 2002-09-06 Nouveaux inhibiteurs de dipeptidylpeptidase i

Country Status (5)

Country Link
EP (1) EP1423410A2 (fr)
JP (1) JP2005511505A (fr)
AU (1) AU2002342657A1 (fr)
DE (1) DE10143840A1 (fr)
WO (1) WO2003022871A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8883714B2 (en) 2008-04-07 2014-11-11 Arena Pharmaceuticals, Inc. Pharmaceutical compositions comprising GPR119 agonists which act as peptide YY (PYY) secretagogues

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040242568A1 (en) 2003-03-25 2004-12-02 Syrrx, Inc. Dipeptidyl peptidase inhibitors
ATE399763T1 (de) 2003-05-30 2008-07-15 Prozymex As Proteasehemmer
US7678909B1 (en) 2003-08-13 2010-03-16 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7169926B1 (en) 2003-08-13 2007-01-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7790736B2 (en) 2003-08-13 2010-09-07 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7790734B2 (en) 2003-09-08 2010-09-07 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7732446B1 (en) 2004-03-11 2010-06-08 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
CN102134229B (zh) 2004-03-15 2020-08-04 武田药品工业株式会社 二肽基肽酶抑制剂
EP1745292A2 (fr) * 2004-04-28 2007-01-24 Bayer HealthCare AG Diagnostics et therapeutiques de maladies associees a la dipeptidyl-peptidase 1 (dpp1)
WO2005118555A1 (fr) 2004-06-04 2005-12-15 Takeda Pharmaceutical Company Limited Inhibiteurs de la dipeptidyl peptidase
WO2006019965A2 (fr) 2004-07-16 2006-02-23 Takeda San Diego, Inc. Inhibiteurs de la dipeptidyl peptidase
WO2006068978A2 (fr) 2004-12-21 2006-06-29 Takeda Pharmaceutial Company Limited Inhibiteurs de dipeptidyle peptidase
DOP2006000008A (es) 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
PL1942898T5 (pl) 2005-09-14 2014-10-31 Takeda Pharmaceuticals Co Inhibitory peptydazy dipeptydylowej do leczenia cukrzycy
CN102675221A (zh) 2005-09-16 2012-09-19 武田药品工业株式会社 用于制备嘧啶二酮衍生物的方法中的中间体
UA97479C2 (ru) 2006-04-11 2012-02-27 Арена Фармасьютикалз, Инк. Применение g-белок-связанного рецептора (gpcr) для идентификации средств, которые усиливают секрецию глюкозозависимого инсулинотропного пептида (gi)
PE20071221A1 (es) 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
AR077642A1 (es) 2009-07-09 2011-09-14 Arena Pharm Inc Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
MX2012011631A (es) 2010-04-06 2013-01-18 Arena Pharm Inc Moduladores del receptor gpr119 y el tratamiento de trastornos relacionados con el mismo.
BR112013008100A2 (pt) 2010-09-22 2016-08-09 Arena Pharm Inc "moduladores do receptor de gpr19 e o tratamento de distúrbios relacionados a eles."
US20140018371A1 (en) 2011-04-01 2014-01-16 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012145361A1 (fr) 2011-04-19 2012-10-26 Arena Pharmaceuticals, Inc. Modulateurs du récepteur gpr119 et traitement de troubles liés à celui-ci
WO2012145603A1 (fr) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulateurs du récepteur gpr119 et traitement de troubles liés à celui-ci
WO2012145604A1 (fr) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulateurs du récepteur gpr119 et traitement de troubles liés à celui-ci
WO2012170702A1 (fr) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulateurs du récepteur gpr119 et traitement de troubles associés à celui-ci
WO2013055910A1 (fr) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulateurs du récepteur gpr119 et traitement de troubles associés
WO2014074668A1 (fr) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulateurs de gpr119 et traitement de troubles associés à ceux-ci
GB201415598D0 (en) 2014-09-03 2014-10-15 Univ Birmingham Elavated Itercranial Pressure Treatment
CA2979033A1 (fr) 2015-03-09 2016-09-15 Intekrin Therapeutics, Inc. Methodes de traitement de la steatose hepatique non alcoolique et/ou de la lipodystrophie
US11253508B2 (en) 2017-04-03 2022-02-22 Coherus Biosciences, Inc. PPARy agonist for treatment of progressive supranuclear palsy
CN113292465B (zh) * 2021-06-17 2022-11-08 贵州医科大学 一种半胱氨酸衍生物及其合成方法、应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998022494A2 (fr) * 1996-11-22 1998-05-28 Elan Pharmaceuticals, Inc. METHODES ET COMPOSES DESTINES A INHIBER LA LIBERATION ET/OU LA SYNTHESE DU PEPTIDE β-AMYLOIDE
EP0995756A2 (fr) * 1998-07-31 2000-04-26 Probiodrug Gesellschaft für Arzneimittelforschung mbH Inhibiteurs orientés a méchanisme du peptidase dipeptidique I

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998022494A2 (fr) * 1996-11-22 1998-05-28 Elan Pharmaceuticals, Inc. METHODES ET COMPOSES DESTINES A INHIBER LA LIBERATION ET/OU LA SYNTHESE DU PEPTIDE β-AMYLOIDE
EP0995756A2 (fr) * 1998-07-31 2000-04-26 Probiodrug Gesellschaft für Arzneimittelforschung mbH Inhibiteurs orientés a méchanisme du peptidase dipeptidique I

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BRÖMME D ET AL: "N,O-diacyl hydroxamates as selective and irreversible inhibitors of cysteine proteinases.", METHODS IN ENZYMOLOGY. UNITED STATES 1994, vol. 244, 1994, pages 671 - 685, XP009008478, ISSN: 0076-6879 *
CHEN SHUI-TEIN ET AL: "One-pot synthesis of cathepsin inhibitors: N-alpha-protected N-peptidyl-O-acetylhydroxylamines catalysed by alcalase followed by lipase in anhydrous t-butanol.", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 2, no. 12, 1992, pages 1685 - 1690, XP009008477, ISSN: 0960-894X *
DATABASE CAPLUS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; XP002236414, retrieved from STN Database accession no. 1998:352863 *
DEMUTH H-U ET AL: "INHIBITION OF PROTEASES WITH ENKEPHALIN-ANALOGUE INHIBITORS", JOURNAL OF ENZYME INHIBITION, NEW YORK, NY, US, vol. 4, no. 4, 1991, pages 289 - 298, XP000876876 *
DEMUTH H-U ET AL: "N-PEPTIDYL O-ACYL HYDROXAMATES: COMPARISON OF THE SELECTIVE INHIBITION OF SERINE AND CYSTEINE PROTEINASES", BBA - PROTEIN STRUCTURE AND MOLECULAR ENZYMOLOGIE, ELSEVIER SCIENCE BV, AMSTERDAM, NL, vol. 1295, no. 2, 18 July 1996 (1996-07-18), pages 179 - 186, XP000876878, ISSN: 0167-4838 *
SMITH R A ET AL: "PEPTIDYL-O-ACYLHYDROXAMATES POTENT NEW INACTIVATORS OF CATHEPSIN B", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 155, no. 3, 1988, pages 1201 - 1206, XP009008480, ISSN: 0006-291X *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8883714B2 (en) 2008-04-07 2014-11-11 Arena Pharmaceuticals, Inc. Pharmaceutical compositions comprising GPR119 agonists which act as peptide YY (PYY) secretagogues

Also Published As

Publication number Publication date
AU2002342657A1 (en) 2003-03-24
WO2003022871A2 (fr) 2003-03-20
DE10143840A1 (de) 2003-03-27
EP1423410A2 (fr) 2004-06-02
JP2005511505A (ja) 2005-04-28

Similar Documents

Publication Publication Date Title
WO2003022871A3 (fr) Nouveaux inhibiteurs de dipeptidylpeptidase i
SE9203825L (sv) Dubbelt verkande inhibitorer foer no-syntas och cyklooxygenas, foerfarande foer framstaellning daerav och terapeutiska kompositioner innehaallande desamma
PH12012501351A1 (en) Synthesis of eporthilones, intermediates thereto, analogues and uses thereof
EP2311851A3 (fr) Inhibitoren der Serinproteasen, insbesondere der HCV-NS3-NS4A-Protease
PL332509A1 (en) Beta-sulphonyl-hydroxamic acids as inhibitors of intercellular substance metaloproteinases
WO2003059898A3 (fr) Analogues d'eponemycine et d'epoxomicine et leurs utilisations
BRPI0212346B1 (pt) Compostos derivados de benzotiadiazepina ou um sal farmaceuticamente aceitável do mesmo com efeito inibidor de transporte de ácido de bile ileal, processo para a preparação dos mesmos, uso destes, e, composição farmacêutica.
CA2367017A1 (fr) Inhibiteurs de l'enzyme impdh
PE20070138A1 (es) Compuestos heterociclicos como inhibidores de aspartil proteasas
MXPA05011150A (es) 2-hidroxi-3-diaminoalcanos de benzamida.
MY138452A (en) Novel process for synthesizing and a novel crystal form of agomelatine as well as pharmaceutical preparations containing these
WO2004113365A3 (fr) Inhibiteurs de la tripeptide hepatite c serine protease
IL143545A0 (en) Thrombin inhibitors
TW200833682A (en) Pharmaceutical compounds
AP1541A (en) New thiadazoles and oxadiazoles and their use as phosphodiesterase - 7 inhibitors.
TR200400003T4 (tr) (S)-2-Ethoxy -3-4-(2-4-Methanesulfonyloxyphenyl ethoxy) propanoic asidin birleştirilmiş hali
HUP9900390A2 (hu) Szerin-proteáz-inhibitorok és ezeket tartalmazó gyógyszerkészítmények
WO2005084222A3 (fr) Synthese d'epothilones, intermediaires, analogues et leurs utilisations
CY1107367T1 (el) Σαρωση για πεπτιδια που αναστελουν προσδεση της pp1c στις πρωτεϊνες bcl-2, bcl-xl και bcl-w
DE602004029355D1 (de) Sulfopyrrolderivate
WO2003022844A3 (fr) Synthese d'epothilones, intermediaires destines a ces dernieres et analogues d'epothilones
Reiter et al. Difluoroketones as inhibitors of matrix metalloprotease-13
DK1144421T3 (da) Phosphiniske pseudopeptider, som er inhibitorer af matrix-metalloproteaser
Kim et al. First hydroxamate inhibitors for carboxypeptidase A. N-Acyl-N-hydroxy-β-phenylalanines
RS20050514A (en) Compounds having prolyl oligopeptidase inhibitory activity

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002779316

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2003526944

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2002779316

Country of ref document: EP